Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, and if approved, tinlarebant would be …